Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 169

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 169
---
, other research programs from Kineta’s development platform, and any other future programs; |

102

| • |     | establishing and maintaining relationships with contract research organizations (“CROs”) and clinical 
 sites for the clinical development of our product candidates and our future product candidates;       |

| • |     | timely receipt of marketing approvals from applicable regulatory authorities for any product candidates for which 
 Kineta successfully completes clinical development;                                                               |

| • |     | transferring Kineta’s manufacturing process to a commercial contract development and manufacturing company, 
 including obtaining finished products that are appropriately packaged for sale;                             |

| • |     | establishing and maintaining commercially viable supply and manufacturing relationships with third parties that                                                                  
 can provide adequate, in both amount and quality, products and services to support clinical development and meet the market demand for Kineta’s product candidates, if approved; |

| • |     | meeting milestones for licensed programs; |

| • |     | successful commercial launch following any marketing approval, including the development of a commercial 
 infrastructure, whether in-house or with one or more collaborators;                                      |

| • |     | a continued acceptable safety profile following any marketing approval of Kineta’s product candidates; |

| • |     | commercial acceptance of Kineta’s product candidates by patients, the medical community and third-party 
 payors;                                                                                                 |

| • |     | satisfying any required post-marketing approval commitments to applicable regulatory authorities; |

| • |     | identifying, assessing and developing new product candidates from Kineta’s development platform; |

| • |     | obtaining, maintaining and expanding patent protection, trade secret protection and regulatory exclusivity, both 
 in the United States and internationally;                                                                        |

| • |     | defending against third-party interference or infringement claims, if any; |

| • |     | entering into, on favorable terms, any collaboration, licensing or other arrangements that may be necessary or 
 desirable to develop, manufacture or commercialize Kineta’s product candidates;                                |

| • |     | obtaining coverage and adequate reimbursement by third-party payors for Kineta’s product candidates; |

| • |     | addressing any competing therapies and technological and market developments; and |

| • |     | attracting, hiring and retaining qualified personnel. |

Kineta may never be successful in achieving its objectives and, even if it does, may never generate revenue that is significant or large enough to achieve profitability. If Kineta does achieve profitability, it may not be able to sustain or increase profitability on a quarterly or annual basis.